Further studies on pituitary and ovarian function in women receiving hormonal contraception.
B L Cohen, M Katz
https://pubmed.ncbi.nlm.nih.gov/6794980/Actively Recruiting
Led by Shady Grove Fertility Reproductive Science Center · Updated on 2026-03-02
394
Participants Needed
3
Research Sites
4 weeks
Total Duration
This trial investigates how pausing combined hormonal contraceptives CHC affects planned egg freezing in women aged 18 to 40. Researchers are studying whether a 2-month break from CHC before starting ovarian stimulation leads to more eggs retrieved compared to starting immediately after stopping CHC. The study aims to understand if hormonal contraceptive use suppresses ovarian reserve markers and affects egg yield during fertility preservation. Participants will be randomly assigned to one of two groups one will take a 2-month break from CHC before egg freezing, and the other will start ovarian stimulation right after stopping CHC. Both groups will undergo planned oocyte cryopreservation procedures. This is a multi-center, randomized, quadruple-blind trial comparing these two approaches to optimize fertility preservation protocols. During the study, participants will have ovarian reserve markers like Anti-Mllerian hormone AMH measured before and after the drug holiday. The main outcomes measured are the number of eggs retrieved and the maturation rate of these eggs during retrieval. The study also monitors changes in AMH levels over 2 months. Participants will be assessed through blood tests and egg retrieval procedures, with safety and procedure tolerance followed throughout the trial.
CONDITIONS
Hormonal Optimization: Late vs. Immediate Start After Discontinuation of Oral Contraceptives in Assisted Reproductive technologY (HOLIDAY)
T
Tasha Newsome, Clinical Research Supervisor
S
Seth J Barishansky, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Shady Grove Fertility Reproductive Science Center
Lead Sponsor
EMD Serono
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | 2-Month Pause of Combined Hormonal Contraceptives Before Oocyte Cryopreservation | Immediate Start of Oocyte Cryopreservation After Stopping Combined Hormonal Contraceptives | Oocyte Cryopreservation Without Mandated Hormonal Pause |
|---|---|---|---|
| What is it? | Participants stop using combined hormonal contraceptives for 2 months before undergoing ovarian stimulation and oocyte cryopreservation. | Participants begin ovarian stimulation and oocyte cryopreservation immediately after stopping combined hormonal contraceptives. | Oocyte cryopreservation is commonly performed without a mandated pause in hormonal contraception; timing of stimulation varies based on individual factors and provider protocol. |
| Role in trial | Investigational trial arm studying whether a hormonal pause before stimulation changes oocyte maturation or retrieval outcomes. | Comparator trial arm evaluating current outcomes with immediate stimulation after stopping hormonal contraception. | Standard clinical protocol in fertility preservation, not assigned as a trial arm. |
| Primary clinical use | To evaluate whether a pause in CHC improves oocyte maturation rate and number of oocytes retrieved during fertility preservation. | To assess outcomes when ovarian stimulation and retrieval begin immediately after stopping contraception. | Standard fertility preservation protocol aims to maximize the number and quality of oocytes retrieved without requiring a hormonal pause. |
| How is it performed? | Participants discontinue combined hormonal contraceptives. After a 2-month wait, undergo ovarian stimulation and oocyte retrieval. | Participants stop hormonal contraceptives and immediately begin ovarian stimulation and oocyte retrieval. | Oocyte cryopreservation typically involves ovarian stimulation and retrieval soon after stopping contraceptives, with timing adjusted to individual and protocol factors. |
| Evidence maturity | Evidence for the benefit of a hormonal pause prior to ovarian stimulation is limited and currently under active investigation in this trial. | Immediate ovarian stimulation after stopping contraceptives is supported by published evidence and widely practiced in fertility preservation. | Oocyte cryopreservation without mandated hormonal pause is evidence-based and accepted as a standard for fertility preservation, with outcomes varying by age and ovarian reserve. |
| Important limitations | Potential delays from the hormonal pause may increase age-related decline in fertility. Lack of published data on clinical outcomes specifically for this regimen. | Immediate stimulation protocols may have varying effects depending on individual ovarian response; not all outcomes are predictable. | Number of oocytes retrieved and future pregnancy rates depend on age and ovarian reserve. No universal protocol fits all patients. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 2 months or immediate
Participants either pause combined hormonal contraceptives for 2 months before planned oocyte cryopreservation or immediately begin planned oocyte cryopreservation after discontinuing contraceptives.
1 to 2 visits depending on group assignment
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
B L Cohen, M Katz
https://pubmed.ncbi.nlm.nih.gov/6794980/B L Cohen, M Katz
https://pubmed.ncbi.nlm.nih.gov/393456/David B Dunson, Donna D Baird, Bernardo Colombo
https://pubmed.ncbi.nlm.nih.gov/14704244/Briana Rudick, Neisha Opper, Richard Paulson...
https://pubmed.ncbi.nlm.nih.gov/20723535/Karl R Hansen, Nicholas S Knowlton, Angela C Thyer...
https://pubmed.ncbi.nlm.nih.gov/18192670/Nam D Tran, Lusine Aghajanova, Chia-Ning Kao...
https://pubmed.ncbi.nlm.nih.gov/26696299/Ernest Hung Yu Ng, Carina Chi Wai Chan, Oi Shan Tang...
https://pubmed.ncbi.nlm.nih.gov/15358718/Glenn L Schattman
https://pubmed.ncbi.nlm.nih.gov/26789885/L S Wan, M Ganguly, G Weiss
https://pubmed.ncbi.nlm.nih.gov/6796328/N Noyes, E Porcu, A Borini
https://pubmed.ncbi.nlm.nih.gov/19490780/Shady Grove Fertility Reproductive Science Center
Lead Sponsor
EMD Serono
Collaborating Sponsor